Project Grant R01CA284565
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$1.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $708,100 Project Grant to the Dana-Farber Cancer Institute, Inc. (Dfci) to conduct research on "Overcoming Rebound Growth of Pediatric Low-Grade Glioas Following MAPK Pathway Inhibition." The grant, which runs from July 1, 2024 to June 30, 2026, will support Dfci's efforts to better understand the mechanisms driving recurrence of pediatric low-grade glioma brain tumors after...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Dana-Farber Cancer Institute, Inc. (DFCI) in the amount of $942,442. The grant, awarded on September 1, 2024, will support research to identify the mechanisms driving rapid evolution of cancer genomes, with a focus on understanding catastrophic mutational processes like chromothripsis and chromoplexy. The research, conducted at DFCI's facilities in Boston, MA,...
The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund research at the University of California, San Francisco (UCSF) to investigate metabolic mechanisms of immunosuppression in diffuse midline gliomas (DMGs), a type of aggressive brain cancer in children. The $686,979 award will support studies to determine how the H3K27M mutation in DMGs upregulates the glycolytic enzyme PGK1, leading to increased citrate production that suppresses...
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $670,904 to The Regents of the University of California, San Francisco (UCSF) from August 7, 2024 to July 31, 2029. The grant supports research aimed at developing combination metabolic therapy and advanced imaging techniques to improve outcomes for patients with diffuse midline glioma (DMG), a devastating form of pediatric brain cancer....
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
The U.S. Department of Defense's Defense Health Agency awarded a $778,092 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant funds research to advance preclinical studies of a dual-targeted, fine-tuned immune-restoring CAR-T cell therapy for the treatment of high-grade serous ovarian cancer. This research aims to develop innovative approaches to understanding, detecting, and treating...
The Department of the Army Medical Command awarded a $884,997 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program. The three-year grant will fund research to intervene in the TP53 pathway phosphatome in pediatric high-grade gliomas. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $456,414 to Seattle Children's Hospital/Seattle Children's Research Institute to conduct a Phase 2 clinical trial evaluating the efficacy of B7-H3 chimeric antigen receptor (CAR) T-cell therapy for children and young adults with diffuse intrinsic pontine glioma (DIPG), a fatal central nervous system tumor. The award will support the trial, which will deliver repeated intracranial...